Patents Assigned to Genentech
  • Methods for diagnosing and treating cancer
    Patent number: 11261498
    Abstract: The present invention provides methods of treating cancer based on the methylation status of the ERBB2 gene. One aspect of the invention provides a method of administering an EGFR inhibitor therapy based on the methylation status of the ERBB2 gene.
    Type: Grant
    Filed: October 2, 2019
    Date of Patent: March 1, 2022
    Assignee: Genentech, Inc.
    Inventors: Thomas E. Januario, David Shames
  • THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20220055977
    Abstract: The invention provides a method of treating a disease or condition in a mammal by administering a compound having the general formula I: or a pharmaceutically acceptable salt thereof, wherein the variables RAA, n, ring A, X1, L, m, X2, R2, R3, R4, R5, X, and R6 have the meaning as described herein.
    Type: Application
    Filed: August 6, 2021
    Publication date: February 24, 2022
    Applicants: GENENTECH, INC., XENON PHARMACEUTICALS INC.
    Inventors: Ivan William HEMEON, Brian SAFINA, Daniel SUTHERLIN
  • PROCESS FOR MAKING ARYLOMYCIN RING ANALOGS
    Publication number: 20220056078
    Abstract: Methods for making an arylomycin ring of formula t or salts or solvates thereof, wherein R, R1, R2, R3, R4, R5, R6, R7, R8, R9, R5, R10 and Pg1 are as defined herein.
    Type: Application
    Filed: November 2, 2021
    Publication date: February 24, 2022
    Applicant: Genentech, Inc.
    Inventors: Filip PETRONIJEVIC, Ngiap-Kie LIM, Nicholas WONG, Allen HONG, Haiyun HOU, Xin LINGHU, Francis GOSSELIN
  • METHODS OF MAKING ANTIBODIES
    Publication number: 20220056134
    Abstract: Provided are, inter alia, methods of improving pairing of a heavy chain and a light chain of an antibody (such as a bispecific antibody). Also provided are antibodies (e.g., bispecific antibodies) generated using such methods, libraries, and methods of screening such libraries.
    Type: Application
    Filed: November 8, 2021
    Publication date: February 24, 2022
    Applicant: Genentech, Inc.
    Inventors: Kamal Kishore JOSHI, Paul J. Carter, Yiyuan Yin
  • PD-L1 promoter methylation in cancer
    Patent number: 11254987
    Abstract: This invention provides methods for the treatment of cancer in subjects having medium or low methylation level in the PD-L1 promoter region. Also provided are related kits and articles of manufacture.
    Type: Grant
    Filed: November 22, 2017
    Date of Patent: February 22, 2022
    Assignee: GENENTECH, INC.
    Inventors: Edward Kadel, Marcin Kowanetz, Kimberly Walter
  • METHODS OF TREATING RHEUMATOID ARTHRITIS, CHRONIC SPONTANEOUS URTICARIA, AND SYSTEMIC LUPUS ERYTHEMATOSIS USING AN INHIBITOR OF BRUTON'S TYROSINE KINASE
    Publication number: 20220047588
    Abstract: The present disclosure relates to methods of treating rheumatoid arthritis, chronic spontaneous urticaria, and systemic lupus erythematosus using fenebrutinib, an inhibitor of Bruton's tyrosine kinase, or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: July 21, 2021
    Publication date: February 17, 2022
    Applicant: Genentech, Inc.
    Inventors: Tamiko KATSUMOTO, Leslie CHINN, Alyssa Mariko MORIMOTO, David James HADDON
  • IMMUNOGLOBULIN A ANTIBODIES AND METHODS OF PRODUCTION AND USE
    Publication number: 20220048990
    Abstract: The presently disclosed subject matter provides antibodies, e.g., IgA antibodies and IgG-IgA fusion molecules, and compositions comprising such antibodies, as well as methods of making and using such antibodies and compositions.
    Type: Application
    Filed: July 20, 2021
    Publication date: February 17, 2022
    Applicant: GENENTECH, INC.
    Inventors: Twyla Noelle Lombana, Julie A. Zorn, Marissa L. Matsumoto, Christoph Spiess, Claudio Ciferri, Alberto Estevez
  • PHOTOCROSSLINKING PEPTIDES FOR SITE SPECIFIC CONJUGATION TO FC-CONTAINING PROTEINS
    Publication number: 20220047711
    Abstract: Provided herein are peptides having a photocrosslinking moiety useful for the synthesis of antibody-drug conjugates as well as methods of making and using such conjugates.
    Type: Application
    Filed: June 8, 2021
    Publication date: February 17, 2022
    Applicant: Genentech, Inc.
    Inventors: Jack SADOWSKY, Neelie Tyana ZACHARIAS
  • Therapeutic compounds and uses thereof
    Patent number: 11247989
    Abstract: The present invention relates to a compound formula (I): and to salts thereof, wherein R1, R2 X, and Y have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.
    Type: Grant
    Filed: November 21, 2018
    Date of Patent: February 15, 2022
    Assignees: GENENTECH, INC., CONSTELLATION PHARMACEUTICALS, INC.
    Inventors: Patrick Cyr, Sarah Bronner, F. Anthony Romero, Steven Magnuson, Vickie Hsiao-Wei Tsui, Jeremy M. Murray, John Wai, Kwong Wah Lai, Fei Wang, Kevin X. Chen
  • SOLID FORMS OF 3-((1R,3R)-1-(2,6-DIFLUORO-4-((1-(3-FLUOROPROPYL)AZETIDIN-3-YL)AMINO)PHENYL)-3-METHYL-1,3,4,9-TETRAHYDRO-2H-PYRIDO[3,4-B]INDOL-2-YL)-2,2-DIFLUOROPROPAN-1-OL AND PROCESSES FOR PREPARING FUSED TRICYCLIC COMPOUNDS COMPRISING A SUBSTITUTED PHENYL OR PYRIDINYL MOIETY, INCLUDING METHODS OF THEIR USE
    Publication number: 20220041587
    Abstract: Provided herein are solid forms, salts, and formulations of 3-((1R,3R)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azetidin-3-yl)amino)phenyl)-3-methyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol, processes and synthesis thereof, and methods of their use in the treatment of cancer.
    Type: Application
    Filed: December 3, 2020
    Publication date: February 10, 2022
    Applicants: Hoffmann-La Roche Inc., GENENTECH, INC.
    Inventors: CHEOL KEUN CHUNG, JIE XU, HANS IDING, KYLE CLAGG, MICHAEL DALZIEL, ALEC FETTES, FRANCIS GOSSELIN, NGIAP-KIE LIM, ANDREW MCCLORY, HAIMING ZHANG, PAROMA CHAKRAVARTY, KARTHIK NAGAPUDI, SARAH ROBINSON
  • APOPTOSIS RESISTANT CELL LINES
    Publication number: 20220041672
    Abstract: The present disclosure relates to eukaryotic cell lines with a stable integrated loss-of-function or attenuation-of-function mutation in each of the Bax and Bak genes. Also provided are methods of producing such cell lines. This disclosure also relates to compositions and cell cultures comprising such cell lines, as well as methods of producing a product, such as a recombinant polypeptide or viral vector, using said cells, compositions and cell cultures.
    Type: Application
    Filed: June 23, 2021
    Publication date: February 10, 2022
    Applicant: GENENTECH, INC.
    Inventors: Shahram MISAGHI, Danming TANG, Amy SHEN, Michael LAIRD
  • METHODS OF TREATING CANCER WITH AN ANTI-PD-L1 ANTIBODY
    Publication number: 20220041734
    Abstract: The present disclosure relates to methods, uses, and kits related to treating cancers by administering an anti-PD-L1 antibody (e.g., atezolizumab) to a patient. In some embodiments, the anti-PD-L1 antibody is administered in 840 mg every 2 weeks or 1680 mg every 4 weeks for two or more cycles.
    Type: Application
    Filed: October 25, 2021
    Publication date: February 10, 2022
    Applicant: Genentech, Inc.
    Inventors: Daniel ShinYu CHEN, Cathleen AHEARN, Alan Bart SANDLER
  • METHODS OF USING ANTI-CD79b IMMUNOCONJUGATES
    Publication number: 20220040153
    Abstract: Provided herein are methods of treating B-cell proliferative disorders in particular Follicular Lymphoma and/or Diffuse Large B-Cell Lymphoma using immunoconjugates comprising anti-CD79b antibodies in combination with additional therapeutic agents.
    Type: Application
    Filed: April 14, 2021
    Publication date: February 10, 2022
    Applicant: Genentech, Inc.
    Inventors: Andrew POLSON, Shang-Fan YU, Yu-Waye CHU, Michael WENGER, Jamie Harue HIRATA, Dan LU
  • FORMULATIONS WITH REDUCED DEGRADATION OF POLYSORBATE
    Publication number: 20220040312
    Abstract: The invention provides methods for making such formulations and methods of using such formulations. The invention further provides methods of reducing polysorbate degradation, methods of reducing the amount of visible and sub-visible particles in an aqueous formulation, and methods of disaggregating polysorbate degradation products comprising adding a cyclodextrin to a formula comprising polysorbate and a polypeptide. The invention also provides aqueous formulations comprising a polypeptide, a polysorbate, and a cyclodextrin with reduced polysorbate degradation.
    Type: Application
    Filed: January 22, 2021
    Publication date: February 10, 2022
    Applicant: Genentech, Inc.
    Inventors: Brian CONNOLLY, Lydia HAMBURG, Emily HOLZ
  • (4-hydroxypyrrolidin-2-yl)-heterocyclic compounds and methods of use thereof
    Patent number: 11242344
    Abstract: The present disclosure relates to bifunctional compounds, which can be used as modulators of targeted ubiquitination. In particular, the present disclosure is directed to compounds which contain on one end a VHL ligand moiety, which binds to the VHL E3 ubiquitin ligase, and on the other end a moiety that binds a target protein such that degradation of the target protein/polypeptide is effectuated. Also disclosed are VHL ligands.
    Type: Grant
    Filed: April 24, 2020
    Date of Patent: February 8, 2022
    Assignee: Genentech, Inc.
    Inventors: Nicole Blaquiere, Peter Dragovich, Lewis J. Gazzard, Thomas Pillow, Steven T. Staben, Binqing Wei, Jianfeng Xin
  • OVARIAN TOXICITY ASSESSMENT IN HISTOPATHOLOGICAL IMAGES USING DEEP LEARNING
    Publication number: 20220036548
    Abstract: The present disclosure relates to a deep learning neural network that can identify corpora lutea in the ovaries and a rules-based technique that can count the corpora lutea identified in the ovaries and infer an ovarian toxicity of a compound based on the count of the corpora lutea (CL). Particularly, aspects of the present disclosure are directed to obtaining a set of images of tissue slices from ovaries treated with an amount of a compound; generating, using a neural network model, the set of images with a bounding box around objects that are identified as the CL within the set of images based on coordinates predicted for the bounding box; counting the bounding boxes within the set of images to obtain a CL count for the ovaries; and determining an ovarian toxicity of the compound at the amount based on the CL count.
    Type: Application
    Filed: October 14, 2021
    Publication date: February 3, 2022
    Applicant: Genentech, Inc.
    Inventor: Fang-Yao HU
  • MULTISPECIFIC ANTIBODIES
    Publication number: 20220033515
    Abstract: The invention provides multispecific antibodies and methods of making and using such antibodies.
    Type: Application
    Filed: April 16, 2021
    Publication date: February 3, 2022
    Applicant: Genentech, Inc.
    Inventors: Germaine FUH, Jenny M. BOSTROM
  • MODIFIED ANTIBODY FCS AND METHODS OF USE
    Publication number: 20220033520
    Abstract: Biological macromolecules have tremendous potential for the treatment of disease of the central nervous system (CNS), however, the presence of the blood brain barrier (BBB) makes achieving a therapeutically relevant antibody concentration extremely challenging. Antibodies with enhanced neutral pH affinity for the neonatal Fc receptor demonstrate improved accumulation in the brain. Variants disclosed herein also enhanced exposure in engineered mouse models. Using an anti-BACE1 antibody, these Fc variants significantly reduced the levels of brain Abeta.
    Type: Application
    Filed: June 9, 2021
    Publication date: February 3, 2022
    Applicant: Genentech, Inc.
    Inventors: Gregory A. Lazar, James Ernst, Jasvinder Atwal, Shraddha Shirish Sadekar, Yanli Yang, Shan Chung
  • COMBINATION THERAPY OF DIFFUSE LARGE B-CELL LYMPHOMA COMPRISING AN ANTI-CD79B IMMUNOCONJUGATES, AN ALKYLATING AGENT AND AN ANTI-CD20 ANTIBODY
    Publication number: 20220031861
    Abstract: Provided herein are methods of treating B-cell proliferative disorders (such as Diffuse Large B-Cell Lymphoma “DLBCL”) using immunoconjugates comprising anti-CD79b antibodies in combination with an alkylating agent (such as bendamustine) and an anti-CD20 antibody (such as rituximab).
    Type: Application
    Filed: June 3, 2021
    Publication date: February 3, 2022
    Applicants: Genentech, Inc., Hoffmann-La Roche Inc.
    Inventors: Jamie Harue HIRATA, Grace Hsiao-Wen KU, Ji CHENG
  • Gene expression markers and treatment of multiple sclerosis
    Patent number: 11236391
    Abstract: The present invention concerns markers of multiple sclerosis, their use, and treatment with IL-17 antagonists, including IL-17 antibodies, of subjects with increased levels of such markers.
    Type: Grant
    Filed: July 27, 2017
    Date of Patent: February 1, 2022
    Assignee: Genentech, Inc.
    Inventors: Michael Townsend, Alvernia Francesca Setiadi, Tracy Staton